




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A

* p<0.05 statistical significance						
Treatment	A. Formulation A (High Dose)	B. Formulation A (Medium Dose)	C. Formulation A (Low Dose)	D. Vehicle	E. Tobramycin Positive control (600ug/ml)	F. Untreated Control
A. Formulation A (High Dose)		0.000*	0.000*	0.000*	0.000*	0.000*
B. Formulation A (Medium Dose)	0.000*		0.000*	0.000*	0.000*	0.000*
C. Formulation A (Low Dose)	0.000*	0.000*		0.000*	0.000*	0.001*
D. Vehicle	0.000*	0.000*	0.000*		0.000*	1.000
E. Tobramycin Positive control (600ug/ml)	0.000*	0.000*	0.000*	0.000*		0.000*
F. Untreated Control	0.000*	0.000*	0.000*	1.000	0.000*	

* p<0.05 compared to All treatments

* p<0.05 compared to C. Formulation A (Low Dose), D. Vehicle, E. Tobramycin Positive control (600ug/ml) and F. Untreated Control

* p<0.05 compared to D. Vehicle, E. Tobramycin Positive control (600ug/ml) and F. Untreated Control

* p<0.05 compared to D. Vehicle and F. Untreated Control

FIG. 6B




FIG. 7




FIG. 8




FIG. 9

Bacterial counts of Methicillin-Resistant *Staphylococcus aureus* MRSA, USA 400 (10⁸)




FIG. 10

Bacterial Counts of *Acinetobacter baumannii* (10⁸)





FIG. 11



FIGS. 12A-12D





FIG. 13



FIGS. 14A-14D




FIG. 15